Anne Merete Tryggestad
Papers
1
Total Citations
30
H-Index
1
About
Anne Merete Tryggestad is a pioneering translational researcher in cancer immunotherapy, with a primary focus on developing personalized dendritic cell (DC) vaccines for high-risk prostate cancer. Her major contribution lies in demonstrating the safety, feasibility, and long-term efficacy of adjuvant DC vaccination following radical prostatectomy, as evidenced by her landmark Phase I/II study—the first-in-man trial of its kind—which has garnered 30 citations. This work addresses the critical challenge of preventing biochemical relapse in patients with aggressive disease, offering a potential pathway to durable remission without the toxicity of conventional therapies. Tryggestad’s research bridges bench-to-bedside innovation, integrating personalized immunology with surgical oncology to improve outcomes for high-risk patients. Her notable achievement includes establishing a proof-of-concept for adjuvant DC vaccines in prostate cancer, paving the way for larger trials and combination immunotherapies. With her work cited by peers in oncology and immunology, Tryggestad stands at the forefront of harnessing the patient’s own immune system to combat residual disease, making her a key figure in the evolution of precision cancer vaccines.
Research Focus
Key Achievements
Top Papers
- 1